Active	Status	Sponsor type	Region	Phase	Filter
3 Active 12 Inactive 15 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
reldesemtiv (CK-2127107) / Astellas, Cytokinetics
COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)	Terminated	3	489	Europe, Canada, US, RoW	Reldesemtiv, Placebo	Cytokinetics	Amyotrophic Lateral Sclerosis	07/23	07/23
COURAGE OLE, NCT05442775 / 2021-004727-33: A Phase 3, Open-Label Extension of COURAGE-ALS (CY 5031)	Terminated	3	71	Europe, Canada, US, RoW	Reldesemtiv	Cytokinetics, Cytokinetics Inc	Amyotrophic Lateral Sclerosis	06/23	06/23
CK-136 / Cytokinetics
NCT05662215: A Single and Multiple Ascending Dose Study of CK-3828136 in Healthy Adult Participants	Terminated	1	57	US	CK-3828136, Placebo for CK-3828136	Cytokinetics	Healthy Participants	08/23	08/23